{
    "nctId": "NCT00247481",
    "briefTitle": "ZD1839 (Iressa\u2122) In Combination With Docetaxel As First-Line Treatment In Patients With Metastatic Breast Cancer",
    "officialTitle": "A Multicentre, Randomised, Double-Blind, Non-Comparative Phase II Trial Of ZD1839 (Iressa\u2122) And Placebo In Combination With Chemotherapy With Docetaxel As First-Line Treatment In Patients With Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 77,
    "primaryOutcomeMeasure": "To estimate the overall response rates (complete response [CR] and partial response [PR]) in the ZD1839-treated group and the placebo-treated group.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed breast cancer at a metastatic stage.\n* Uni- or bi-dimensionally measurable lesions (10 mm or 20 mm) according to the Response Evaluation Criteria in Solid Tumours (RECIST) criteria\n* World Health Organisation (WHO) performance status (PS) of 0 to 2\n* Life expectancy of greater than 12 weeks\n* Normal cardiac function (left ventricular ejection fraction \\[LVEF\\] by isotopic examination greater than or equal to 55%)\n\nExclusion Criteria:\n\n* Symptomatic lepto-meningeal metastasis\n* Concomitant infectious disease\n* Any unresolved chronic toxicity greater than CTC grade 2 from previous anticancer therapy\n* Incomplete healing from previous oncologic or other surgery\n* Absolute neutrophil count (ANC) less than 1.5 x 109/litre (L) or platelets less than 100 x 109/L\n* Serum creatinine greater than 1.5 times the ULRR or clearance \\< 60 ml/min\n* ALT or AST greater than 2.5 times the ULRR\n* ALP \\> 5 times the ULRR\n* ALP \\> 2.5 times the ULRR and ALT or AST greater than 1.5 times the ULRR",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}